Drug Database
ME

measles vaccine (live-attenuated)

✓ Approved

Beijing Tiantan Biological Products · Vaccine · Vaccine

What is measles vaccine (live-attenuated)?

measles vaccine (live-attenuated) is a vaccine developed by Beijing Tiantan Biological Products. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyBeijing Tiantan Biological Products
Drug ClassVaccine, Large Molecules
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Beijing Tiantan Biological Products

Therapeutic Indications

measles vaccine (live-attenuated) is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeasles✓ Approved

Related Research Articles

PubMedAdvances in virology2026-09-20

Comparative Sequence Analysis of the Envelope Gene of Kyasanur Forest Disease Virus Vaccine Strain With Currently Circulating Field Strains.

Kaje Keerthi K, Marinaik Chandranaik B CB, Gomes Amitha Reena AR, Rizwan Apsana A et al.

The present study was undertaken with the objective of performing comparative sequence analysis of the envelope (E) gene of Kyasanur forest disease virus (KFDV) vaccine strain P9605 with the circulating field strains. The study was taken up as the currently used KFDV vaccine strain, KFDV P9605, was isolated in the 1960s. For this study, we designed two sets of primers targeting the complete amplification of the E gene of KFDV. The sequencing was performed by the Sanger method, and the deduced sequence of the vaccine virus was deposited in GenBank with accession number PX067005. This sequence obtained for the vaccine virus was aligned and compared with sequences of GenBank-deposited circulating field strains. We also performed comparative sequence analysis of the Kyasanur forest disease (KFD) vaccine seed virus having passaged twice in mouse brain with the vaccine seed virus passaged six times in mouse brain to investigate whether multiple passages in mouse brain will lead to genetic mutation in the immunologically important E gene. The phylogenetic analysis revealed seven amino acid mutations in the field strains at positions A123T, S158N, D178E, D239N, A313S, M429I, and G479A when compared with the vaccine strain. We did not find any mutations at the critical fusogenic segment (residues 98-113) in the E gene of currently circulating field strains compared to the vaccine seed virus. The study found no genetic variations in the E gene of the KFD virus passed two times and passed six times in mouse brain. We performed SWISS-MODEL homology modeling, AlphaFold protein analysis, and Ramachandran plot analysis to study the E protein structures and stability. The observations made in this study suggest slow evolutionary drift and conserved structural stability of the envelope gene of KFDV ever since its emergence 7 decades ago; however, the functional implications of these amino acid substitutions need further studies on their roles in viral infectivity, transmission, and impact on immunity.

PMID 42763584
Read full article →
PubMedJournal of inflammation research2026-09-20

Dimethyl Sulfoxide Modulates T Cell-Mediated Immunity to Attenuate Influenza A Virus Infection.

Jeng Po-Hsuan PH, Tsai Meng-Wei MW, Huang Shing-Hwa SH, Huang Tien-Ru TR et al.

Influenza A virus (IAV) remains a major threat because vaccines provide limited cross-protection and antiviral resistance is rising. Dimethyl sulfoxide (DMSO) is immunomodulatory, but its effect on IAV has not been tested in vivo. We evaluated its efficacy and mechanism in a murine H1N1 model. Male C57BL/6 mice were intranasally challenged with an LD50 of A/Puerto Rico/8/1934 (H1N1) and given daily subcutaneous DMSO (0.22 g/kg/day) or phosphate-buffered saline (PBS) on days 1-7. Survival was monitored for 21 days; lung and bronchoalveolar lavage fluid (BALF) were collected on day 8. Lung histology (hematoxylin and eosin), BALF cytokines (sandwich ELISA), lung and splenic IFN-γ-producing CD4+ and CD8+ T cells (flow cytometry), and whole-lung RNA sequencing (differential expression, KEGG enrichment) were assessed. BALF viral burden was measured by neuraminidase activity assay and TCID50. In vitro, splenic CD8+ T cells exposed to 0%, 0.5%, or 1.0% DMSO were immunoblotted for lymphocyte-activation gene 3 (LAG3). DMSO significantly improved 21-day survival and attenuated alveolar inflammatory infiltration. Day-8 BALF viral titers were significantly lower with DMSO (mean 2.2×103 vs 4.3×104 TCID50/mL; p = 0.034), as was neuraminidase activity. BALF IFN-γ and TGF-β were elevated, whereas TNF-α, IL-6, and IL-1β were not. IFN-γ+ CD8+ T cells increased in the lung but not the spleen; CD4+ populations were unchanged. RNA sequencing showed enrichment of cytokine-cytokine receptor interaction and PI3K/Akt signaling and upregulation of T-box factors, PPAR-γ, and Nek kinases. In vitro, DMSO accelerated LAG3 induction in CD8+ T cells within 12-48 h. DMSO is associated with attenuated IAV severity, a lower day-8 airway viral burden, and a localized expansion of IFN-γ-producing CD8+ T cells, without a concomitant rise in the pro-inflammatory cytokines TNF-α, IL-6, or IL-1β. These associations are correlative and support further investigation of DMSO as a host-directed adjunct for influenza.

PMID 42763701
Read full article →
PubMedIn vitro models2026-09-20

Anti-biofilm and anti-virulence properties of Ricinus communis and Catharanthus roseus leaves against Pseudomonas aeruginosa PAO1.

Gebaly Eman El EE, Taha Mostafa N MN, Ashour Hossam M HM, Khairalla Ahmed S AS

Pseudomonas aeruginosa remains a major concern in clinical microbiology owing to its intrinsic multidrug resistance and its elaborate regulatory networks that enable evasion of host immune responses, particularly through robust biofilm development and the secretion of diverse virulence factors. These pathogenic behaviors are tightly governed by quorum-sensing (QS) systems, prompting increasing interest in exploiting plant-derived compounds as potential anti-virulence therapeutics. In this study, leaf extracts from Ricinus communis and Catharanthus roseus were examined for their capacity to modulate biofilm formation and QS-regulated virulence gene expression in the P. aeruginosa PAO1 strain. The production of key virulence factors was evaluated using multiple standardized assays, including the crystal violet binding assay (biofilm), azocasein assay (protease), chloroform-HCl extraction (pyocyanin), and the orcinol assay (rhamnolipids), while gene expression was quantified via quantitative real-time polymerase chain reaction (qPCR). The findings indicated that the extracts, rich in tannins and flavonoids, did not affect the planktonic growth of PAO1; however, both significantly (P < 0.05) suppressed biofilm formation and attenuated the production of pyocyanin, protease, and rhamnolipids. Additionally, qPCR analysis revealed pronounced downregulation of central QS regulatory genes, lasI, lasR, and rhlR, highlighting the potential of these phytochemicals to disrupt quorum-sensing-mediated pathogenicity.

PMID 42763502
Read full article →
PubMedCureus2026-09-20

GLT6D1 rs1537415 G Allele and Advanced Periodontitis: A Meta-Analysis.

Karaoulas Theofanis A TA, Xirouchakis Christoforos C, Neophytou Chariklia C, Fragkioudakis Ioannis I

This meta-analysis aimed to evaluate the association of the GLT6D1 rs1537415 G allele with susceptibility to periodontitis stage III/IV, grade B or C. Adhering to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, three eligible studies were identified through comprehensive searches of PubMed, Web of Science, and Scopus. Data from 2,185 participants (668 cases and 1,517 controls) were analyzed using random-effects models to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Heterogeneity was assessed using Chi² and I² statistics. Formal testing for publication bias was precluded by the small number of studies (n = 3). The meta-analysis demonstrated a significant association between the rs1537415 G allele and severe periodontitis, with a pooled OR of 1.58 (95% CI: 1.28-1.95). Subgroup analyses showed consistent associations in European and Sudanese populations, whereas no significant association was observed in the Brazilian cohort. Sensitivity analysis excluding the largest Genome-Wide Association Study (GWAS) attenuated the association to a non-significant level (OR = 1.37; 95% CI: 0.87 to 2.16), indicating that a single study largely drove the overall effect; the pooled estimate should therefore be interpreted with caution. The GLT6D1 rs1537415 G allele may represent a genetic risk factor for severe periodontal diseases, particularly stage III/IV and grade B/C, suggesting a possible role in immune modulation. Further research involving larger, multi-ethnic cohorts is crucial to validate these associations and explore gene-environment interactions.

PMID 42763709
Read full article →
PubMedIranian journal of pharmaceutical research : IJPR2026-09-20

Protective Effect of Methoxsalen on Spinal Cord Injury in the Rat Model via Regulation of the PI3K/Akt Pathway.

Zhaohu Mao M, Zheng Zhang Z, Qunqun Shan S

Spinal cord injury (SCI) is a major cause of disability, and the management of secondary injury remains challenging. This study evaluated the protective effects of methoxsalen against SCI and investigated its potential mechanism of action. Network pharmacology and molecular docking were performed to identify the molecular targets of methoxsalen for the treatment of SCI. SCI was induced in rats by laminectomy, and methoxsalen (12 and 24 mg/kg, p.o.) was administered for 14 days after SCI induction. Motor function was assessed using the Basso, Beattie, and Bresnahan (BBB) score, and spinal cord inflammation was evaluated by assessing water deposition and inflammatory cytokine levels in SCI rats. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to assess the mRNA expression of phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) in SCI rats. Molecular docking data showed that methoxsalen interacted with AKT, PI3K, and nuclear factor-κB (NF-κB), with binding energies of -9.1, -9.2, and -9.4 kcal/mol, respectively. The BBB score was significantly improved in the methoxsalen-treated group compared with the SCI group. MDA (18.6 ± 0.9 nmol/mg) and ROS (1.30 ± 0.04-fold) levels were significantly reduced, whereas GSH (92.0 ± 2.2 µM/mg) and SOD (54.2 ± 1.3 U/mg) levels were increased in the methoxsalen-treated group compared with the SCI group. Methoxsalen treatment ameliorated inflammatory alterations and cytokine levels in rats with SCI. The mRNA expression of PI3K, AKT, and NF-κB was attenuated in spinal cord tissue from methoxsalen-treated rats with SCI. Methoxsalen treatment improved motor function in rats with SCI by modulating the PI3K/AKT signaling pathway.

PMID 42763726
Read full article →
PubMedClinical ophthalmology (Auckland, N.Z.)2026-09-20

Real-World Analysis of Switching Between Ranibizumab Biosimilars: Safety and Results - a Multicenter Retrospective Observational Study.

Chakraborty Debdulal D, Sinha Tushar Kanti TK, Biswas Rupak Kanti RK, Maiti Aniruddha A et al.

To describe disease-specific visual, anatomical, treatment-exposure, and documented safety outcomes over 24 weeks among eyes undergoing availability-driven switching between ranibizumab biosimilars in routine retinal practice in India. This multicenter retrospective observational cohort study reviewed records from January to December 2024. Baseline was the index-switch visit, before administration of the substituted ranibizumab biosimilar. Only one eye per patient was included; when both eyes were eligible, the right eye was selected by convention. Eligible eyes had at least one documented availability-driven biosimilar-to-biosimilar switch and complete 24-week follow-up. Outcomes were summarized descriptively because there was no non-switch comparator group. Of 742 screened eyes, 595 eyes from 595 patients met the inclusion criteria and received 1625 intravitreal ranibizumab biosimilar injections over 24 weeks (mean, 2.73 injections per eye). One switch was recorded in 466 eyes (78.3%) and two switches in 129 eyes (21.7%). Mean BCVA improved from 0.57 logMAR at baseline to 0.26 at 12 weeks and 0.32 at 24 weeks; the early visual improvement therefore attenuated modestly by week 24 but remained better than baseline. Mean central macular thickness decreased from 490.4 micrometers at baseline to 273.6 micrometers at 24 weeks. At final follow-up, 369 eyes (62.0%) gained at least two lines and 488 eyes (82.0%) maintained or improved vision. No endophthalmitis, retinal detachment, or treatment-related systemic adverse event was documented in the available clinical records. Eyes exposed to availability-driven switching between ranibizumab biosimilars showed favorable short-term visual and anatomical outcomes over 24 weeks. Because this retrospective study lacked a non-switch comparator and protocol-mandated safety or immunogenicity surveillance, it cannot establish an effect attributable to switching, comparative safety, equivalence, or formal interchangeability.

PMID 42763736
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about measles vaccine (live-attenuated)